Global Beta-thalassemia (B-thal) Market, by Treatment (Iron Chelating Drugs, Erythroid Maturation Agents, Stem Cell Therapy, and Others), by Disease Indication (Beta Thalassemia Minor, Beta Thalassemia Intermedia, and Beta Thalassemia Major), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 411.8 million in 2021 and is expected to exhibit a CAGR of 7.8% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
Robust product pipeline for the treatment of beta-thalassemia is expected to drive the growth of global beta-thalassemia (B-thal) market over the forecast period.
For instance, on September 20, 2021, Vifor (International) Inc., a biotechnology company initiated a phase 2b, double-blind, randomised, placebo-controlled, multicentre study to assess the efficacy and safety of VIT-2763 multiple doses in adults with transfusion-dependent beta-thalassaemia. The study is estimated to complete by July 2023.
Moreover, on October 16, 2020, Imara, Inc., a clinical-stage biopharmaceutical company, initiated a phase 2 study to evaluate the safety and tolerability of IMR-687 in subjects with beta thalassemia. The study is estimated to complete by May 2022.
Furthermore, on August 17, 2021, EdiGene (GuangZhou) Inc., a clinical-stage biotechnology company, initiated a multicenter, open label phase I study to evaluate the safety and efficacy of a single dose of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) in subjects with transfusion dependent β-Thalassaemia. The study is estimated to complete by June 30, 2024.
Global Beta-thalassemia (B-thal) Market – Impact of Coronavirus (Covid-19) Pandemic
Thalassemia patients, especially young adults/adults, have a chronic condition which may be associated with several co-morbidities linked to the underlying disease as well as complications of chronic transfusions, including heart failure, pulmonary hypertension, and diabetes. Thus, it seems possible that there could be an increased risk of more severe COVID-19 disease in some patients. Nonetheless, outcomes were recently reported from a small cohort of Italian patients followed in the northern part of Italy, where the pandemic has been the most widespread, showing most experienced relatively mild to moderate COVID-19 disease. The number of infected thalassemia patients was lower than expected, likely due to earlier and more vigilant self-isolation compared to the general population.
Moreover, at present there is no evidence that the SARS-CoV-2 virus may be transmitted through donated blood. It is advisable to maintain the individual’s chronic transfusion regimen. Clinics and infusion centres should offer patients the safest possible environment for receiving transfusions, in areas free of COVID-19 patients or those being screened for respiratory symptoms and providing health care personnel protective equipment.
Furthermore, no data is available regarding iron chelation and susceptibility to COVID-19 or severity of infection. If a patient is exposed but asymptomatic there is no reason to interrupt iron chelation. If a patient becomes symptomatic, particularly with moderate to severe disease, then interruption of iron chelation is advisable, with ongoing communication between the treating physicians and the hematologist. Several comorbidities in thalassemia are related to iron overload. Patients should be reminded that adherence to the iron chelation dose and schedule recommended by their thalassemia care provider will reduce organ injury and thalassemia complications.
Browse 38 Market Data Tables and 31 Figures spread through 192 Pages and in-depth TOC on “Beta-thalassemia (B-thal) Market”- Global Forecast to 2028, by Treatment (Iron Chelating Drugs, Erythroid Maturation Agents, Stem Cell Therapy, and Others), by Disease Indication (Beta Thalassemia Minor, Beta Thalassemia Intermedia, and Beta Thalassemia Major), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),
To know the latest trends and insights prevalent in the global beta-thalassemia (B-thal) market, click the link below:
https://www.coherentmarketinsights.com/market-insight/beta-thalassemia-market-4793
Key players operating in the market are focusing on research collaboration in order to develop and get regulatory approval for the novel product for the treatment of beta-thalassemia is expected to drive the growth of global beta-thalassemia (B-thal) market over the forecast period.
For instance, in June 2021, Bristol Myers Squibb and Acceleron Pharma Inc., a biopharmaceutical company, collaboratively announced the first data from the phase II BEYOND study evaluating Reblozyl (luspatercept-aamt), a first-in-class erythroid maturation agent, plus best supportive care in adult patients with non-transfusion dependent (NTD) beta thalassemia, were presented at the European Hematology Association (EHA) 2021 Virtual Congress as part of its Presidential Symposium. Results demonstrated that 77.7% of patients treated with Reblozyl achieved a hemoglobin increase (≥1.0 gram/deciliter) compared to 0% of patients in the placebo arm in the Europe.
Key Takeaways of the Global Beta-thalassemia (B-thal) Market:
- The global beta-thalassemia (B-thal) market is expected to exhibit a CAGR of 7.8% over the forecast period, owing presence of strong pipeline products. For instance, on September 24, 2020, Ionis Pharmaceuticals, Inc., a biopharmaceutical company, initiated a phase 2a, randomized, open-label study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of ISIS 702843 administered subcutaneously to patients with non-transfusion dependent β-thalassemia intermedia. The study is estimated to complete by October 2023.
- Among treatment, erythroid maturation agents segment is accounted for largest market share in 2020, owing to market players focusing on obtaining drug approvals. For instance, on February 16, 2021, Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc., a biopharmaceutical company, announced that Health Canada has approved REBLOZYL (luspatercept for injection) for the treatment of adult patients with transfusion-dependent anemia requiring at least two RBC red blood cell (RBC) units over 8 weeks resulting from very low-to intermediate-risk myelodysplastic syndromes (MDS) who have ring sideroblasts and who have failed or are not suitable for erythropoietin-based therapy. REBLOZYL represents a new class of treatment for eligible patients as the first and only approved erythroid maturation agent in Canada.
- Key players operating in the global beta-thalassemia (B-thal) market include Celgene Corp., BlueBird Bio, Protagonist Therapeutics, Agios Pharmaceuticals, Ionis Pharmaceuticals, Vifor Pharma, Orchard Therapeutics, Sangamo Therapeutics, CRISPR Therapeutics, DisperSol Technologies, Kiadis Pharma, Incyte Corporation, Editas Medicine, Global Blood Therapeutics, and Syros Pharmaceuticals.
